AI주식인사이트AI Stock Insight
C

파마리서치

214450KOSDAQ의료용품 및 기타 의약 관련제품 제조업

46.9 / 100

Reference Date: 2026-04-13

Financial Score16.5 / 40
News Sentiment14.4 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is above the industry average but the high debt ratio poses financial risk. Declined 5.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Parmaresearch is a biopharmaceutical company specializing in regenerative medicine, leveraging PDRN/PN technology to develop and sell pharmaceuticals, medical devices, and cosmetics. Established in 2013 with a GMP-certified factory in Gangneung and expanded with a second plant in 2019, the company's key products include Regenix, Rejuran, and Conjuuran. It plans to expand into Asian, European, and North American markets, while its subsidiary also operates a botulinum toxin business.

Number of Employees

526people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
20.22Industry Average 19.893.0Point

Higher than industry avg (caution)

PBR
4.33Industry Average 1.620.0Point

2.7x industry avg (risky)

ROE
26.02Industry Average -4.893.5Point

Well below industry avg

Debt Ratio
28.95Industry Average 8.880.0Point

3.3x industry avg (risky)

Trend 2023~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲43.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲53.4% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 20.6% (improving, 3yr)

Detailed News Sentiment

10 totalPositive 2Neutral 3Negative 0Average Sentiment Score 65

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 302,000Won52-week high 711,00052-week low 282,500
1-month return2.0Point

1m -5.03% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-09
  • Neutral기업가치제고계획(자율공시)2026-03-30
  • Neutral정기주주총회결과2026-03-27
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
  • Neutral감사보고서제출2026-03-19